{"id":"W4399570686","doi":"10.1200/jco.2024.42.16_suppl.tps8651","title":"Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated <i>KRAS G12C+</i>advanced non-small cell lung cancer (NSCLC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Pemetrexed; Medicine; Pembrolizumab; Chemotherapy; Lung cancer; Oncology; KRAS; Lung; Internal medicine; non-small cell lung cancer (NSCLC); Phases of clinical research; Cancer; Cancer research; Cisplatin; Colorectal cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001774077,0.001923184,0.002229743,0.0005492273,0.0004265637,0.001257393,0.001366439,0.001401912,0.004721017],"category_scores_gemma":[0.0006667636,0.0009121678,0.001812432,0.0005222035,0.001120012,0.0009115522,0.0004195989,0.003832329,0.001363369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001625311,"about_ca_system_score_gemma":0.003155194,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002166897,"about_ca_topic_score_gemma":0.007975011,"domain_scores_codex":[0.9996401,0.0001262886,0.00001975867,0.00006647007,0.00004955386,0.00009776648],"domain_scores_gemma":[0.9993156,0.00006247738,0.00009797795,0.00004941303,0.00004653501,0.0004279439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6800343,0.1766088,0.006648964,0.002065519,0.002148295,0.0002935636,0.0003153108,0.002416781,0.04559262,0.0004788084,0.00588874,0.07750829],"study_design_scores_gemma":[0.5627567,0.4213969,0.007102061,0.00006844056,0.0007471194,0.0003583865,0.0001058521,0.0006840454,0.003177656,0.000187431,0.003377488,0.00003797358],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846522,0.003739808,0.0004533037,0.0005725558,0.0002392632,0.005414873,0.002196633,0.0001486071,0.002582854],"genre_scores_gemma":[0.9747594,0.005307301,0.002119795,0.001506748,0.0002418486,0.004667242,0.006642385,0.00005475783,0.004700594],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004721017,"threshold_uncertainty_score":0.01579338,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04445174887146803,"score_gpt":0.4896304343599229,"score_spread":0.4451786854884549,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}